An arm of the European Medicines Agency (EMA) has recommended expanding the European approval of Johnson & Johnson‘s Tecvayli (teclistamab) to treat adults with…
News
The experimental immunotherapy IGV-001 may improve survival outcomes in certain people with an aggressive form of glioma called glioblastoma (GBM), according to a new…
The U.S. Food and Drug Administration (FDA) has given GT Biopharma a green light to start a Phase…
POLYCYTHEMIA VERA
Targeting inflammation may help control polycythemia vera
Inflammation plays a key role in the progression of polycythemia vera (PV), making it an important potential treatment target. In a new Perspective article,…
Artificial intelligence (AI) may help design better CAR T-cell therapies to treat myeloma and other cancers, a study showed. An AI-designed CAR…
PANCREATIC CANCER
Newly approved pancreatic cancer drug wins breakthrough therapy status
The U.S. Food and Drug Administration (FDA) has awarded its breakthrough therapy designation — which aims to speed the development of promising new medications —…
Treatment with Tecvayli (teclistamab), an approved cancer drug, can reduce the risk of disease progression in people with high-risk smoldering multiple myeloma, an…
The overall risk of any infection in the first year after starting treatment is similar in people given different types of immune-modulating therapies for…
Bristol Myers Squibb‘s experimental cell therapy arlocabtagene autoleucel (arlo-cel) may help control myeloma that has returned or failed…
A CAR T-cell therapy targeting glioblastoma improved tumor control and survival in mice when given before surgery rather than afterward, according to a new study.
Recent Posts
- Trial finds treatment eases PV symptoms despite missing main goal
- The quiet courage of taking a short break as a caregiver
- EU clears Tecvayli as solo option when myeloma returns after first treatment
- Blood marker changes may help track glioblastoma progression
- Social media can be a scary place for myeloma patients